Global Immune Thrombocytopenia Drugs Market 2019-2023
SKU ID : TNV-14326691 | Publishing Date : 29-May-2019 | No. of pages : 136
Detailed TOC of Global Immune Thrombocytopenia Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
TPO-RAs - Market size and forecast 2018-2023
Corticosteroids - Market size and forecast 2018-2023
IVIGs - Market size and forecast 2018-2023
Other drugs - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Special regulatory designations
Increasing number of awareness programs
Development of biosimilars
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global hematology drugs market
Exhibit 02: Segments of global hematology drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: TPO-RAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Approved TPO-RAs
Exhibit 21: Pipeline of TPO-RAs
Exhibit 22: TPO-RAs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Some of the generic sponsors for corticosteroids
Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%)
Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Some of the available IVIGs
Exhibit 28: Side effects of IVIGs
Exhibit 29: Approximate Costs of IVIGs
Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%)
Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Off-label drugs for immune thrombocytopenia
Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%)
Exhibit 34: Market opportunity by product
Exhibit 35: Customer landscape
Exhibit 36: Market share by geography 2018-2023 (%)
Exhibit 37: Geographic comparison
Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: North America - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in North America
Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in Europe
Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 45: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 46: Top 3 countries in Asia
Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 48: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 49: Top 3 countries in ROW
Exhibit 50: Key leading countries
Exhibit 51: Market opportunity
Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia
Exhibit 53: Drug development pipeline for immune thrombocytopenia
Exhibit 54: Side effects associated with available drugs
Exhibit 55: Alternative therapies for immune thrombocytopenia
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Drug designations
Exhibit 58: Vendor landscape
Exhibit 59: Landscape disruption
Exhibit 60: Vendors covered
Exhibit 61: Vendor classification
Exhibit 62: Market positioning of vendors
Exhibit 63: Amgen Inc. - Vendor overview
Exhibit 64: Amgen Inc. - Business segments
Exhibit 65: Amgen Inc. - Organizational developments
Exhibit 66: Amgen Inc. - Geographic focus
Exhibit 67: Amgen Inc. - Key offerings
Exhibit 68: Amgen Inc. - Key customers
Exhibit 69: CSL Ltd. - Vendor overview
Exhibit 70: CSL Ltd. - Business segments
Exhibit 71: CSL Ltd. - Organizational developments
Exhibit 72: CSL Ltd. - Geographic focus
Exhibit 73: CSL Ltd. - Segment focus
Exhibit 74: CSL Ltd. - Key offerings
Exhibit 75: CSL Ltd. - Key customers
Exhibit 76: Horizon Therapeutics Plc - Vendor overview
Exhibit 77: Horizon Therapeutics Plc - Business segments
Exhibit 78: Horizon Therapeutics Plc - Organizational developments
Exhibit 79: Horizon Therapeutics Plc - Geographic focus
Exhibit 80: Horizon Therapeutics Plc - Segment focus
Exhibit 81: Horizon Therapeutics Plc - Key offerings
Exhibit 82: Horizon Therapeutics Plc - Key customers
Exhibit 83: Merck & Co. Inc. - Vendor overview
Exhibit 84: Merck & Co. Inc. - Business segments
Exhibit 85: Merck & Co. Inc. - Organizational developments
Exhibit 86: Merck & Co. Inc. - Geographic focus
Exhibit 87: Merck & Co. Inc. - Segment focus
Exhibit 88: Merck & Co. Inc. - Key offerings
Exhibit 89: Merck & Co. Inc. - Key customers
Exhibit 90: Novartis AG - Vendor overview
Exhibit 91: Novartis AG - Business segments
Exhibit 92: Novartis AG - Organizational developments
Exhibit 93: Novartis AG - Geographic focus
Exhibit 94: Novartis AG - Segment focus
Exhibit 95: Novartis AG - Key offerings
Exhibit 96: Novartis AG - Key customers
Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview
Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments
Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments
Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings
Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers
Exhibit 102: Validation techniques employed for market sizing
Exhibit 103: Definition of market positioning of vendors
Keyplayers in Global Immune Thrombocytopenia Drugs Market 2019-2023
Amgen Inc.CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.